

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/167872 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C12Q 1/6876 (2018.01)
A61K 39/00 (2006.01) G01N 33/574 (2006.01)
C12N 15/113 (2010.01) G01N 33/48 (2006.01)
A61K 48/00 (2006.01) A61P 35/00 (2006.01)
C12Q 1/6886 (2018.01)

(21) International Application Number:

PCT/US2024/014520

(22) International Filing Date:

05 February 2024 (05.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/443,659 06 February 2023 (06.02.2023) US

(71) Applicant: **GMP BIOTECHNOLOGY LIMITED**

[—/CN]; Unit 2212, 22/F, CC Wu Building, 302-308 Hennessy Road Wanchai, Hong Kong, China (CN).

(72) Inventor; and

(71) Applicant: **TRIEU, Vuong** [US/US]; Suite 107, 29397 Agoura Road, Agoura Hills, California 91301 (US).

(74) Agent: **ECKMAN, Richard R.**; Second Floor, 530 Lytton Ave, Palo Alto, California 94301 (US).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: MTOR THERAPEUTICS FOR CANCER

FIG. 1



(57) **Abstract:** This invention relates to methods, agents and uses for treating cancer. More particularly, this invention discloses methods, agents and uses for inhibiting and/or suppressing mTOR, which can provide improved clinical outcomes for cancer. This invention provides stable formulations of new mTOR agents, including antisense oligonucleotide structures, as well as combinations with other agents and therapies for treating cancer. This invention includes aspects for selecting subjects or sub-populations who benefit from mTOR agents against cancer.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*